Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;11(2):435-446.
doi: 10.21037/cdt-20-906.

MALAT1 gene rs600231 polymorphism positively associated with acute coronary syndrome in Chinese population: a case-control study

Ning Song  1   2 , Jun-Yi Luo  1   2 , Qian Zhao  1 , Jin-Yu Zhang  3 , Fen Liu  1   2 , Xiao-Mei Li  1   2 , Yi-Ning Yang  1   2
Affiliations

MALAT1 gene rs600231 polymorphism positively associated with acute coronary syndrome in Chinese population: a case-control study

Ning Song et al. Cardiovasc Diagn Ther. 2021 Apr.

Abstract

Background: Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has been recognized as a major player in the pathogenesis of coronary artery disease (CAD). The aim of the study was to determine the association between polymorphisms of the MALAT1 gene and acute coronary syndrome (ACS) in a Chinese population in Xinjiang.

Methods: In the case-control study, we genotyped three nucleotide polymorphisms (rs3200401, rs4102217, rs600231) of the MALAT1 gene using SNPscanTM typing assays (1,053 controls and 929 ACS patients). Furthermore, we explored a predictive model using MALAT1 rs600231 and clinical variables to predict the risk of ACS. Finally, the relative expression of long noncoding RNA (lncRNA) MALAT1 was also measured in 92 ACS patients and 92 controls using quantitative real-time polymerase chain reaction (qRT-PCR).

Results: The prevalence of the GG genotype of rs600231 in ACS group was higher than that in control group (15.7% vs. 14.7%, P=0.048). The dominant model differed (AG + GG vs. AA) and the G allele of rs600231 in ACS group was higher than that in control group (for dominant model: 66.2% vs. 60.9%, P=0.014; for allele: 41.0% vs. 37.8%, P=0.042). Multivariate logistic regression analysis and the predictive nomogram model showed that the dominant model of rs600231 remained an independent risk factor for ACS [odds ratio (OR) =1.32, 95% confidence interval (CI): 1.07-1.63, P=0.009]. The area under the receiver operating characteristic (ROC) curve (AUC) for the nomogram model for the prediction of ACS was 0.738 (95% CI: 0.716-0.761). In addition, in the AG and GG phenotypes, the relative expression of lncRNA MALAT1 was significantly higher in ACS patients than in controls with the same phenotypes (P<0.05). Among ACS group, compared to other genotype carriers, the relative expression level of MALAT1 in GG genotype carriers was higher (P<0.05).

Conclusions: The present study suggested that the AG and GG genotype of rs600231 in MALAT1 gene was independently associated with ACS, and could be a risk genetic marker of ACS in a Chinese population in Xinjiang.

Keywords: Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1); acute coronary syndrome (ACS); polymorphism.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/cdt-20-906). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Predictive nomogram for ACS. (A) Nomogram of ACS risk for patients. (B) Calibration plot of the nomogram model. (C) ROC curve analysis of predictive model. ACS, acute coronary syndrome; ROC, receiver operating characteristic; HDL-C, high-density lipoprotein-cholesterol; TC, total cholesterol.
Figure 2
Figure 2
Influence of the MALAT1 gene polymorphism rs600231 on lncRNA MALAT1 expression in ACS patients and healthy controls in PBMCs. *, P<0.05. MALAT1, metastasis-associated lung adenocarcinoma transcript 1; lncRNA, long noncoding RNA; ACS, acute coronary syndrome; PBMC, peripheral blood mononuclear cell.
See this image and copyright information in PMC

References

    1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017;135:e146-603. Erratum in: Circulation 2017;135:e646. Erratum in: Circulation 2017;136:e196. 10.1161/CIR.0000000000000485 - DOI - PMC - PubMed
    1. Shibata T, Kawakami S, Noguchi T, et al. Prevalence, clinical features, and prognosis of acute myocardial infarction attributable to coronary artery embolism. Circulation 2015;132:241-50. 10.1161/CIRCULATIONAHA.114.015134 - DOI - PubMed
    1. Zhang H, Masoudi FA, Li J, et al. National assessment of early β-blocker therapy in patients with acute myocardial infarction in China, 2001-2011: The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study. Am Heart J 2015;170:506-15.e1. 10.1016/j.ahj.2015.05.012 - DOI - PMC - PubMed
    1. Hartman MHT, Eppinga RN, Vlaar PJJ, et al. The contemporary value of peak creatine kinase-MB after ST-segment elevation myocardial infarction above other clinical and angiographic characteristics in predicting infarct size, left ventricular ejection fraction, and mortality. Clin Cardiol 2017;40:322-8. 10.1002/clc.22663 - DOI - PMC - PubMed
    1. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006;48:1-11. 10.1016/j.jacc.2006.02.056 - DOI - PubMed